Oligonucleotide compositions and their use to induce apoptosis
AssigneeBioniche Life Sciences Inc.
InventorsNigel C. Phillips, Mario C. Filion, Zdenek Richard Holan
Life of this patent
Estimating the term…
Abstract
The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.
Claims23
A composition comprising a synthetic oligonucleotide sequence of 3 to 9 bases in length comprising at least one nebularine base, at least one hypoxanthine base, or at least one uracil base, or a combination thereof.
A method of inducing a cellular response comprising administration to a cell of a composition comprising a synthetic oligonucleotide sequence of 3 to 9 bases in length comprising at least one nebularine base, at least one hypoxanthine base, or at least one uracil base, or a combination thereof, and an acceptable carrier.
A method of treating a disease or condition characterized by undesired cellular proliferation in an animal or a human comprising administration to the animal or the human of an effective amount of a composition comprising a synthetic oligonucleotide sequence of 3 to 9 bases in length comprising at least one nebularine base, at least one hypoxanthine base, or at least one uracil base, or a combination thereof and an acceptable carrier.
Dependencies are inferred from the claim text.